ArticleMedicine2026
Differences in response to dienogest therapy among different phenotypes of endometriosis: A single-center retrospective cohort analysis.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aims to investigate the differences in response to dienogest (DNG) therapy among patients with 3 different phenotypes of endometriosis: ovarian endometrioma (OMA), superficial peritoneal endometriosis (SUP), and deep infiltrating endometriosis (DIE). This study was a single-center retrospective cohort analysis. A total of 501 consecutive patients with endometriosis diagnosed and treated in our hospital from January 2023 to January 2024 were enrolled and divided into the OMA group (n = 276), SUP group (n = 125), and DIE group (n = 100) based on imaging/surgical phenotypes. All patients received monotherapy with DNG (2 mg/day) for at least 6 months. Differences in pain visual analog scale (VAS) scores, lesion size, serum CA125 levels, quality of life (36-Item Short Form Health Survey), and adverse reactions before and after treatment were compared among the 3 groups. Multivariate logistic regression analysis was used to identify independent influencing factors for significant pain relief (defined as ≥50% reduction in VAS score). At baseline, disease duration, revised American Society for Reproductive Medicine stage and score, CA125 levels, and pain intensity in the DIE group were significantly higher than those in the OMA and SUP groups (P < .001). After 6 months of treatment, pain VAS scores, lesion size, and CA125 levels significantly decreased from baseline in all 3 groups (P < .001). Intergroup comparisons showed statistically significant differences in the reduction of VAS scores (ΔVAS) for dysmenorrhea and chronic pelvic pain (P < .01), with the SUP group showing the smallest improvement. Meanwhile, the lesion reduction rate in the OMA group was significantly higher than that in the SUP and DIE groups (47.5% vs 39.4% vs 37.9%, P < .001). Multivariate regression analysis showed that, compared with the OMA phenotype, the DIE phenotype was an independent negative predictor for significant pain relief (odds ratio = 0.67, 95% confidence interval: 0.43-0.99, P = .046). DNG is significantly effective for all 3 endometriosis phenotypes, effectively relieving pain, reducing lesion size, and improving quality of life. However, patients with the DIE phenotype, due to the inherently more severe nature of their disease, have a relatively lower likelihood of achieving significant pain relief and a higher incidence of adverse reactions, necessitating special attention in clinical management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.